Background {#Sec1}
==========

Sub-Saharan Africa (SSA) countries are undergoing demographic and epidemiological transition with the double burden of non-communicable and infectious diseases \[[@CR1]\]. The adoption of western lifestyles, mostly in urban areas, contributes to increase the prevalence of hypertension and diabetes mellitus in this setting \[[@CR2]--[@CR4]\]. The above factors are associated with glomerular diseases and constitute the main etiological factors for chronic kidney disease (CKD) in SSA \[[@CR5], [@CR6]\]. CKD is emerging as one of the major health threats, affecting 10 % of adults worldwide and contributing every year to millions of premature deaths \[[@CR7], [@CR8]\]. Few studies have been conducted on CKD epidemiology in SSA \[[@CR9]\]. These studies mostly of low methodological quality have revealed huge disparities in the prevalence of CKD across SSA regions depending on the definition, method for assessing glomerular filtration rate (GFR) and targeted population \[[@CR4], [@CR9]--[@CR14]\].

In central Africa, previous studies have reported a high prevalence of CKD which affects young adults in their productive years; being higher in high risk groups such as people with hypertension, diabetes mellitus, obesity or HIV infection \[[@CR10]--[@CR12]\]. The present report presents findings from a study on the prevalence and risk factors of CKD in urban Cameroon.

Methods {#Sec2}
=======

Study setting and design {#Sec3}
------------------------

We carried a cross-sectional study of two months duration from March to April 2013 in all health areas of the Cité des Palmiers health district in the Littoral region of Cameroon. The Cité des Palmiers health district is the second largest and populous health district in Douala, the economic Capital of Cameroon. It comprises eight health areas with an estimated population of 423,253 inhabitants in 2012. The population is diversified representing the different ethnic and social groups in the country, and comprises students, traders, civil servants, housewives, and low, middle and high income earners from private sectors. This study was approved by the Cameroon National Ethics Committee.

We used a multistage cluster sampling to recruit 500 participants as Sumaili et al. in Kinshasa \[[@CR11]\], corresponding to 62--63 subjects per health area. Sampling stages included the health area (first stage), the neighbourhood (second stage) and individuals (third stage). Adults were informed through community leaders, posters, leaflets and words of mouth, and requested to report to the chieftainship. All adults who reported on the day of recruitment benefited from a sensitization campaign, followed by a random selection of study participants and data collection.

Data collection {#Sec4}
---------------

Final year undergraduate medical students collected data between 8 a.m. to 12 a.m. for participants who provided a written informed consent. They used a pre-designed questionnaire to collect socio-demographic data (age, gender and occupation) and clinical information including personal history of existing conditions (hypertension, diabetes and gout), lifestyle characteristics (alcohol consumption and smoking), use of nephrotoxic agents (herbal medicines, foods addictive and street medicines), anthropometric measurements (weight, height and waist girth) and blood pressure variables. Blood pressure was measured according to the World Health Organization (WHO) guidelines \[[@CR15]\] using an automated sphygmomanometer (OMRON HEM705CP, Omron Matsusaka Co, Matsusaka City, Mie-Ken, Japan) on the right arm with participants in a sitting position. All anthropometric measurements were performed three times and their average used in all analyses. In every participant, we drew 3 ml of whole blood from an antecubital vein into dry tubes for serum creatinine and collected mid-stream second morning urine for dipstick tests.

Dipstick tests were performed immediately after sample collection while blood specimens for serum creatinine were transported on ice-cooled containers to the biochemistry laboratory of the Douala General Hospital for processing. Urine dipstick tests were performed with CombiScreen 7SL PLUS 7 test strips (Analyticon Biotechnologies AG, D-35104 Lichentenfeis, Germany). Serum creatinine was measured with a kinetic modification of the Jaffé reaction using Human visual spectrophotometer (Human Gesellschaft, Biochemica und Diagnostica mbH, Wiesbaden, Germany) and Beckman creatinine analyzer (Beckman CX systems instruments, Anaheim, CA, USA). For any participant with positive dipstick \[protein (at least traces), blood, leucocytes)\], another urine sample was collected 2 to 3 weeks later to confirm the results. We excluded 11 (2.2 %) pregnant women and seven (1.4 %) participants with concomitant leucocyturia and urine nitrites.

Definitions and calculations {#Sec5}
----------------------------

Estimated glomerular filtration rate (eGFR, mL/min) used the Cockcroft-Gault (CG), the four-variable Modification of Diet in Renal Disease (MDRD) study and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations \[[@CR16]--[@CR18]\]. CKD was defined by a confirmed positive dipstick albuminuria (at least traces) and/or eGFR \< 60 ml/min/1.73 m^2^ according to K/DIGO guidelines which were used to stage participants for CKD \[[@CR19]\]. eGFR classification was the following: G1 (eGFR ≥ 90); G2 (eGFR 60--89); G3a (eGFR 45--59); G3b (eGFR 30--44); G4 (eGFR 15--29) and G5 (eGFR \< 15). Albuminuria was classified as: A1 (negative); A2 (trace to 1+) and A3 (at least 2+). Decreased GFR corresponded to any eGFR \< 60 ml/min regardless the equation used. The following formula was used to convert serum creatinine from Jaffé reaction (SCr~Jaffé~) to standardized serum creatinine (SCr~Standardized~) to be used in MDRD and CKD-EPI formulas: SCr~Standardized~ = 0.95\*SCr~Jaffé~ -- 0.10 \[[@CR20], [@CR21]\]. Hypertension was defined as a systolic (SBP) ≥140 mmHg and/or a diastolic blood pressure (DBP) ≥90 mmHg or being on antihypertensive drugs. Diabetes was defined as self-reported history of doctor diagnosed condition or use of glucose control agents.

Statistical analysis {#Sec6}
--------------------

Data analysis used SPSS® v.17 software for Windows® (SPSS Inc., Chicago, USA). We have reported the results as means and standard deviations, and counts and percentages. The Fisher exact test, Student *t*-test and Mann--Whitney *U* test were used to compare qualitative and quantitative variables across subgroups defined by sex, status for albuminuria, decreased GFR and CKD according to different GFR estimators. Age and sex adjusted logistic regression models were used to investigate the predictors of CKD. A *p*-value \<0.05 was used to indicate statistically significant results.

Results {#Sec7}
=======

Baseline characteristics of the study population {#Sec8}
------------------------------------------------

The mean age was 45.3 years, similarly between men and women (*p* = 0.267), Table [1](#Tab1){ref-type="table"}. Alcohol (68.9 vs. 37.8 %), tobacco use (12.7 vs. 0.4 %), and systolic blood pressure (137 vs. 128 mmHg) were higher in men compared to women (all *p* \< 0.001). However, compared with men, women were more likely to have a history of hypertension (15.5 vs. 9.4 %, *p* = 0.041), to have high body mass index (BMI, 28.6 vs. 25.8 kg/m^2^, *p* \< 0.001)), and to be overweight or obese (68.2 vs. 53.6 %, *p* = 0.001), Table [1](#Tab1){ref-type="table"}. We observed a higher prevalence of CKD risk factors including hypertension (38.6 %), overweight and obesity (60.4 %), and longstanding use of herbal (57.8 %) and street (29.6 %) medicines in the study sample. As expected, serum creatinine was higher in men than women (*p* \< 0.001) but women had a significantly higher mean estimated creatinine clearance by the CKD-EPI equation (103.5 vs. 95.5 ml/min, *p* = 0.005). Furthermore, estimated creatinine clearance was highest with CKD-EPI equation and lowest with the MDRD equation.Table 1Baseline characteristics, kidney function test and urine profile by sexCharacteristicsOverallMenWomen*P*n (%)500 (100)267 (53.4)233 (46.6)-Mean age, years (SD)45.3 (13.2)45.9 (13.5)44.6 (12.8)0.267History of hypertension (%)61 (12.2)25 (9.4)36 (15.5)0.041History of diabetes (%)14 (2.8)6 (2.2)8 (3.4)0.433History of gout (%)6 (1.2)4 (1.5)2 (0.9)0.690Tobacco use currently or formerly (%)35 (7.0)34 (12.7)1 (0.4)\<0.001Alcohol use currently or formerly (%)272 (54.4)184 (68.9)88 (37.8)\<0.001Longstanding use of herbal medicine (%)289 (57.8)160 (59.9)129 (55.4)0.303Longstanding use of street medicine (%)148 (29.6)81 (30.3)67 (28.8)0.768Mean SBP, mmHg (SD)132 (24)137 (23)128 (24)\<0.001Mean DBP, mmHg (SD)81 (15)82 (15)81 (14)0.267Any hypertension (%)193 (38.6)109 (40.8)84 (36.1)0.311Mean BMI, kg/m^2^ (SD)27.1 (5.3)25.8 (3.9)28.6 (6.3)\<0.001BMI \> 25 (%)302 (60.4)143 (53.6)159 (68.2)0.001Pulse (SD)77 (13)74 (13)79 (12)\<0.001Dipstick abnormalities (%) Albuminuria0.542  A1464 (92.8)246 (92.1)218 (93.6)  A229 (5.8)18 (6.7)11 (4.7)  A37 (1.4)3 (0.6)4 (0.8)Mean serum creatinine (jaffe), mg/dl (SD)10.5 (2.6)11.7 (2.6)9.1 (1.8)\<0.001Mean serum creatinine (standardized), mg/dl (SD)9.9 (2.5)11.0 (2.5)8.6 (1.7)\<0.001Mean Creatinine clearance, ml/min (SD) MDRD93.7 (24.9)93.8 (25.3)93.7 (24.5)0.981 CG97.8 (24.9)96.5 (24.8)99.4 (24.9)0.201 CKD-EPI99.2 (31.4)95.5 (28.6)103.5 (33.9)0.005Stages of kidney function (eGFR), (%) MDRD\>90259 (51.8)139 (52.1)120 (51.5)0.98360--90214 (42.8)114 (42.7)100 (42.9)45--5924 (4.8)11 (4.1)13 (5.6)30--442 (0.4)2 (0.7)0 (0.0)15--291 (0.2)1 (0.3)0 (0.0) CG\>90296 (59.2)155 (58.1)141 (60.5)0.85460--90160 (32.0)88 (33.0)72 (30.9)45--5933 (6.6)16 (6.0)17 (7.3)30--4410 (2.0)7 (2.6)3 (1.3)15--291 (0.2)1 (0.4)0 (0.0) CKD-EPI\>90301 (60.2)152 (56.9)149 (63.9)0.20660--90177 (35.4)104 (39.0)73 (31.3)45--5919 (3.8)8 (3.0)11 (4.7)30--442 (0.4)2 (0.7)0 (0.0)15--291 (0.2)1 (0.3)0 (0.0)*A* albuminuria, *BMI* body mass index, *CG* Cockroft-Gault, *CKD-EPI* chronic kidney disease epidemiology collaboration, *DBP* diastolic blood pressure, *eGFR* estimated glomerular filtration rate, *MDRD* Modification of Diet in Renal Disease, *SBP* systolic blood pressure, *SD* standard deviation

Staging of kidney function and prevalence of chronic kidney disease {#Sec9}
-------------------------------------------------------------------

The staging of kidney function according to various estimators is presented in Table [1](#Tab1){ref-type="table"}. In general, there was no sex difference in the staging of kidney function, regardless of the estimator (all p \> 0.206). None of the participants was in stage G5 regardless of the estimators used. Similar proportions of stages G3b and G4 were observed with CKD-EPI and MDRD estimators. The prevalence of albuminuria was 7.2 % while the prevalence of decreased GFR (eGFR \< 60 ml/min) was 4.4, 5.4 and 8.8 % respectively based on GFR estimated from the CKD-EPI, MDRD and CG equations (Table [2](#Tab2){ref-type="table"}). The prevalence of CKD (any albuminuria and/or eGFR \< 60 ml/min) was 10.0, 11.0 and 14.2 % respectively for CKD-EPI, MDRD and CG equations (Table [3](#Tab3){ref-type="table"}).Table 2Baseline characteristics by status for albuminuria and decreased GFR based on various kidney function estimatorsVariablesAlbuminuriaeGFR \< 60 (MDRD)eGFR \< 60 (CG)eGFR \< 60 (CKD-EPI)NoYes*P*NoYes*P*NoYes*p*NoYes*p*n (%)464 (92.8)36 (7.2)473 (94.6)27 (5.4)456 (91.2)44 (8.8)478 (95.6)22 (4.4)Sex (women)218 (47.0)15 (41.7)0.605220 (46.5)13 (48.1)\>0.999213 (46.7)20 (45.5)\>0.999222 (46.4)11 (50.0)0.828Mean age, years (SD)44.8 (13.0)52.0 (14.1)0.00244.4 (12.7)61.4 (10.9)\<0.00143.6 (12.1)62.9 (11.1)\<0.00144.3 (12.6)66.0 (9.1)\<0.001History of HTA (%)50 (10.8)11 (30.6)0.00249 (10.4)12 (44.4)\<0.00148 (10.5)13 (29.5)0.00149 (10.3)12 (54.5)\<0.001History of diabetes (%)10 (2.2)4 (11.1)0.01410 (2.1)4 (14.8)0.00510 (2.2)4 (9.1)0.02710 (2.1)4 (18.2)0.002History of goutte (%)4 (0.9)2 (5.6)0.0636 (1.3)0\>0.9996 (1.3)0\>0.9996 (1.3)0\>0.999Tobacco use (%)33 (7.1)2 (5.6)\>0.99934 (7.2)1 (3.7)0.71134 (7.5)1 (2.3)0.34835 (7.3)00.389Alcohol use (%)255 (55.0)17 (47.2)0.390259 (54.8)13 (48.1)0.554253 (55.5)19 (43.2)0.153262 (54.8)10 (2.0)0.512Longstanding use of herbal medicine (%)268 (57.8)21 (58.3)\>0.999271 (57.3)18 (66.7)0.424264 (57.9)25 (56.8)\>0.999275 (57.5)14 (63.6)0.662Longstanding use of street medicine (%)133 (28.7)15 (41.7)0.128143 (30.2)5 (18.5)0.278135 (29.6)31 (29.5)\>0.999142 (29.7)6 (27.3)\>0.999Mean SBP, mmHg (SD)132 (23)138 (32)0.199132 (24)142 (31)0.033131 (23)144 (32)0.001132 (24)145 (33)0.011Mean DBP, mmHg (SD)81 (14)85 (22)0.09481 (14)86 (22)0.07481 (14)84 (19)0.16881 (14)86 (22)0.136Any hypertension (%)174 (37.5)19 (52.8)0.077174 (36.8)19 (70.4)0.001166 (36.4)27 (61.4)0.002176 (36.8)17 (77.3)\<0.001Mean BMI, kg/m^2^ (SD)27.1 (5.3)27.4 (5.8)0.71227.0 (5.2)29.0 (7.0)0.05527.4 (5.3)23.4 (3.5)\<0.00127.0 (5.2)28.5 (7.2)0.200BMI \> =25 (%)280 (60.3)22 (61.1)\>0.999284 (60.0)18 (66.7)0.549287 (62.9)15 (34.1)\<0.001289 (60.5)13 (59.1)\>0.999Pulse (SD)76 (12)81 (14)0.04376.5 (12.6)77.6 (14.9)0.67077 (13)76 (14)0.88776 (13)79 (16)0.448*BMI* body mass index, *CG* cockroft-Gault, *CKD-EPI* chronic kidney disease epidemiology collaboration, *DBP* diastolic blood pressure, *eGFR* estimated glomerular filtration rate, *MDRD* Modification of Diet in Renal Disease, *SBP* systolic blood pressure, *SD* standard deviationTable 3Baseline characteristics by status for chronic kidney disease based on various kidney function estimatorsVariablesCKD (MDRD)CKD (CKD-CG)CKD (CKD-EPI)NoYes*P*NoYes*p*NoYes*p*n (%)445 (89.0)55 (11.0)429 (85.8)71 (14.2)450 (90.0)50 (10.0)Sex (women)208 (46.7)25 (45.5)0.887201 (46.9)32 (46.6)0.799210 (46.7)23 (46.0)\>0.999Mean age, years (SD)44.1 (12.7)54.7 (13.4)\<0.00143.4 (12.1)56.9 (13.6)\<0.00144.1 (12.4)56.1 (14.2)\<0.001History of hypertension (%)44 (9.9)17 (30.9)\<0.00142 (9.8)19 (26.8)\<0.00144 (9.8)17 (34.0)\<0.001History of diabetes (%)8 (1.8)6 (10.9)0.0028 (1.9)6 (8.5)0.0088 (1.8)6 (12.0)0.001History of gout (%)4 (0.9)2 (3.6)0.1344 (0.9)2 (2.8)0.2044 (0.9)2 (4.0)0.113Tobacco use (%)32 (7.2)3 (5.5)0.78532 (7.5)3 (4.2)0.45333 (7.3)2 (4.0)0.561Alcohol use (%)245 (55.1)27 (49.1)0.473238 (55.5)34 (47.9)0.249248 (55.1)24 (48.0)0.371Longstanding use of herbal medicine (%)256 (57.5)33 (60.0)0.774249 (58.0)40 (56.3)0.797260 (57.8)29 (58.0)\>0.999Longstanding use of street medicine (%)130 (29.2)18 (32.7)0.639124 (28.9)24 (33.8)0.403129 (28.7)19 (38.0)0.192Mean SBP, mmHg (SD)132 (24)138 (29)0.081131 (23)140 (30)0.008132 (24)139 (30)0.052Mean DBP, mmHg (SD)81 (14)85 (19)0.07681 (14)94 (18)0.13881 (14)84 (19)0.127Any hypertension (%)161 (36.2)32 (58.2)0.002154 (35.9)39 (54.9)0.004163 (36.2)30 (60.0)0.002Mean BMI, kg/m^2^ (SD)27.0 (12.6)28.2 (6.5)0.10727.4 (5.3)25.2 (5.1)0.00227.0 (5.2)27.9 (6.5)0.268BMI \> =25 (%)267 (60.0)35 (63.6)0.663269 (62.7)33 (46.5)0.012272 (60.4)30 (60.0)\>0.999Pulse (SD)76 (13)78 (14)0.34476 (13)77 (13)0.65176 (13)79 (14)0.236*BMI* body mass index, *CG* Cockroft-Gault, *CKD* chronic kidney disease, *CKD-EPI* chronic kidney disease epidemiology collaboration, *DBP* diastolic blood pressure, *MDRD* Modification of Diet in Renal Disease, *SBP* systolic blood pressure, *SD* standard deviation

Correlates of albuminuria, decreased GFR and CKD {#Sec10}
------------------------------------------------

The distribution of baseline characteristics according to the presence of albuminuria, decreased GFR or CKD is shown in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}. Advanced age and known hypertension and diabetes status were significantly associated with albuminuria, decreased GFR and CKD regardless the equation used meanwhile any hypertension was associated with decreased GFR and CKD. Decreased GFR and CKD estimated by CG were associated with increased BMI and overweight/obesity.

Age and sex adjusted predictors of albuminuria, decreased GFR and CKD {#Sec11}
---------------------------------------------------------------------

Age and sex adjusted predictors of albuminuria, decreased GFR and CKD are presented in Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"} separately for each of the estimators. Advanced age was consistently and positively associated with all these outcomes, with the magnitude of the effects per year increase in age being 4 % (95%CI: 1--7 %) for albuminuria, 11 % (7--16 %) to 17 % (11--23 %) for decreased GFR, and 6 % (4--9 %) to 9 % (7--12 %) for CKD. With the exception of decreased GFR and CKD estimated by the CG estimator, known hypertension status was also significantly and positively associated with all the outcomes; meanwhile existing diabetes was borderline associated with albuminuria \[OR 3.05 (95%CI: 0.98--12.8), *p* = 0.055\], and CKD based on MDRD \[3.22 (0.99--10.45), *p* = 0.051\] and CKD-EPI \[3.36 (1.02--11.07), *p* = 0.046\] equations. Increasing BMI was significantly and negatively associated with CG-defined decreased GFR and CKD, and positively with MDRD and CKD-EPI defined decreased GFR, but not CKD. As a consequence, overweight/obesity was associated with lower odd of CG defined decreased GFR \[0.11 (0.05--0.26), *p* \< 0.001\] and CKD \[0.30 (0.17--0.54), *p* \< 0.001\]. The small number of outcomes precluded expanded multivariable regression analysis.Table 4Predictors of albuminuria and decreased GFR in age and sex adjusted logistic regressionsVariablesAlbuminuriaeGFR \< 60 (MDRD)eGFR \< 60 (CG)eGFR \< 60 (CKD-EPI)OR (95 % CI)*p*OR (95 % CI)*p*OR (95 % CI)*p*OR (95 % CI)*p*Sex (women)0.86 (0.43--1.72)0.6610.75 (0.33--1.75)0.5120.81 (0.39--1.69)0.5750.61 (0.23--1.64)0.325Age, per years1.04 (1.01--1.07)0.0021.11 (1.07--1.16)\<0.0011.16 (1.11--1.20)\<0.0011.17 (1.11--1.23)\<0.001History of hypertension2.70 (1.18--6.17)0.0193.42 (1.41--8.28)0.0071.40 (0.61--3.22)0.4225.93 (2.06--17.05)0.001History of diabetes3.05 (0.98--12.8)0.0552.59 (0.63--10.56)0.1841.02 (0.23--4.52)0.9742.88 (0.61--13.54)0.180History of gout6.17 (1.07--35.61)0.042≅00.999≅00.999≅00.999Tobacco use0.70 (0.15--3.15)0.6420.65 (0.08--5.51)0.6950.33 (0.04--2.95)0.324≅00.998Alcohol use0.58 (0.28--1.22)0.1521.29 (0.51--3.26)0.5842.19 (0.96--4.96)0.0611.18 (0.39--3.59)0.771Longstanding use of herbal medicine1.01 (0.50--2.03)09701.67 (0.6904.03)0.2561.03 (0.50--2.15)0.9301.50 (0.54--4.15)0.432Longstanding use of street medicine1.65 (0.82--3.33)0.1620.40 (0.14--1.15)0.0890.74 (0.34--1.64)0.4640.70 (0.24--2.06)0.517SBP, mmHg1.00 (0.99--1.01)0.8941.01 (0.99--1.02)0.8811.00 (0.99--1.02)0.6751.00 (0.99--1.02)0.640DBP, mmHg1.01 (0.99--1.03)0.3671.01 (0.98--1.03)0.4941.00 (0.97--1.02)0.7161.01 (0.98--1.04)0.576Any hypertension1.28 (0.62--2.67)0.5061.85 (0.74--4.60)0.1850.97 (0.45--2.08)0.9422.48 (0.80--7.68)0.116BMI, per kg/m^2^1.01 (0.94--1.08)0.7731.09 (1.01--1.18)0.0320.71 (0.62--0.81)\<0.0011.10 (1.00--1.20)0.055BMI \> =250.89 (0.43--1.83)0.7541.09 (0.43--2.74)0.8550.11 (0.05--0.26)\<0.0010.72 (0.25--2.08)0.544Pulse1.03 (1.00--1.05)0.0481.00 (0.97--1.04)0.8020.99 (0.96--1.02)0.5741.01 (0.98--1.05)0.477*BMI* body mass index, *CG* Cockroft-Gault, *CKD-EPI* chronic kidney disease epidemiology collaboration, *DBP* diastolic blood pressure, *eGFR* estimated glomerular filtration rate, *MDRD* Modification of Diet in Renal Disease, *SBP* systolic blood pressure, *SD* standard deviationTable 5Predictors of chronic kidney disease in age and sex adjusted logistic regressionsVariablesCKD (MDRD)CKD (CG)CKD (CKD-EPI)OR (95 % CI)*p*OR (95 % CI)*p*OR (95 % CI)*p*Sex (women)1.05 (0.59--1.89)0.8561.07 (0.62--1.87)0.8051.10 (0.59--2.04)0.759Age, per years1.06 (1.04--1.09)\<0.0011.09 (1.07--1.12)\<0.0011.08 (1.05--1.10)\<0.001History of HTA2.40 (1.19--4.82)0.0141.61 (0.82--3.16)0.1642.66 (1.30--5.41)0.007History of diabetes3.22 (0.99--10.45)0.0511.79 (0.53--5.99)0.3483.36 (1.02--11.07)0.046History of gout3.95 (0.68--23.01)0.1263.02 (0.50--18.01)0.2264.62 (0.78--27.27)0.091Tobacco use0.76 (0.21--2.70)0.6700.55 (0.15--2.00)0.3660.55 (0.12--2.48)0.432Alcohol use0.65 (0.35--1.23)0.1880.56 (0.31--1.02)0.0600.63 (0.32--1.22)0.171Longstanding use of herbal medicine1.12 (0.62--2.04)0.6990.94 (0.54--1.64)0.8381.03 (0.55--1.91)0.934Longstanding use of street medicine1.05 (0.56--1.96)0.8791.09 (0.61--1.94)0.7781.38 (0.73--2.60)0.325SBP, mmHg1.00 (0.99--1.01)0.8641.00 (0.99--1.01)0.8881.00 (0.99--1.01)0.916DBP, mmHg1.00 (0.99--1.02)0.6161.00 (0.98--1.01)0.7201.00 (0.98--1.02)0.849Any hypertension1.44 (0.77--2.66)0.2491.01 (0.57--1.80)0.9641.44 (0.75--2.76)0.269BMI, per kg/m^2^1.04 (0.98--1.10)0.1700.88 (0.82--0.94)\<0.0011.03 (0.97--1.09)0.384BMI \> =250.92 (0.49--1.71)0.7970.30 (0.17--0.54)\<0.0010.74 (0.39--1.42)0.364Pulse1.01 (0.99--1.03)0.4401.00 (0.98--1.02)0.8721.01 (0.99--1.04)0.308*BMI* body mass index, *CG* Cockroft-Gault, *CKD* chronic kidney disease, *CKD-EPI* chronic kidney disease epidemiology collaboration, *DBP* diastolic blood pressure, *MDRD* Modification of Diet in Renal Disease, *SBP* systolic blood pressure, *SD* standard deviation

Discussion {#Sec12}
==========

Our study assessed the prevalence and correlates of CKD in an urban adults Cameroonian population using the commonest estimators of kidney function. It revealed a high frequency of CKD and related risk factors in this population, with over one in ten participants having CKD regardless of whether CG, MDRD or CKD-EPI equations were used to estimate kidney function. This high prevalence of CKD appeared to be driven mostly by advanced age, hypertension, diabetes mellitus and adiposity.

Our study met the criteria of high quality applied in the meta-analysis by Stanifer et al., and revealed a higher prevalence of CKD in this setting, regardless the estimators used, in line with the findings of the meta-analysis and previous studies in Central and Western Africa region \[[@CR9], [@CR11], [@CR14]\]. These results confirm the already suggested high burden of CKD in SSA setting. CKD prevalence rates in our setting approximate those reported in other low-to-middle income countries and implies that CKD is not affecting only high-income countries \[[@CR22]--[@CR25]\]. Furthermore, much higher prevalence rates have been reported in high risk groups such as hypertensive, diabetes, obese and HIV infected patients in SSA, inviting targeted and proactive screening of these patients \[[@CR10]\]. However, lower prevalence rates have been observed in a country like Senegal, in spite of similar high frequency of CKD risk factors \[[@CR4]\]. The discrepancy could be explained by the differences in CKD definition used as well as methods for assessing urinary albumin excretion and serum creatinine. The reported higher prevalence rate of CKD could be explained by the epidemiological transition; there is a dual burden of diseases in this setting characterized by the growing prevalence and the lower awareness, treatment adherence and control rates of non-communicable diseases, and the increase nephrotoxicity of drugs used in the treatment of communicable disease \[[@CR1], [@CR4], [@CR11], [@CR26]--[@CR28]\].

Across estimators of GFR, the CG equation diagnosed more participants with decreased GFR and CKD while CKD-EPI and MDRD with ethnicity correction diagnosed about the same proportion of participants with both conditions, largely in line with existing and extensively discussed reports from previous studies \[[@CR11], [@CR13], [@CR14]\]. The observed higher GFR estimated by CKD-EPI equation compared to others estimators could be related to the fact that this equation performed better than others especially at higher GFR \[[@CR17], [@CR18]\].

Regardless of the estimators used to assess CKD, advanced age, hypertension, diabetes mellitus and adiposity were the risk factors of CKD observed in this study as reported elsewhere \[[@CR4], [@CR11]--[@CR13]\]. These are well known clinical and socio-demographic risk factors for CKD occurrence and progression to end stage renal disease (ESRD) \[[@CR19]\]. Moreover, hypertension and diabetes mellitus are associated with glomerular diseases and constitute the main etiological factors for CKD in SSA \[[@CR5], [@CR6]\]. These findings invite appropriate management of such factors and an array of actions to tackle them as well as implementation of sensitization campaign to raise awareness, increase treatment adherence and improve control rate. This is important to reduce the growing prevalence of ESRD patients in this lower middle income country where social security programs are inexistent, and where patients with CKD are referred late to nephrologists \[[@CR29], [@CR30]\]. Furthermore, in Cameroon for instance, and in spite of government's subsidies, patients with ESRD on renal replacement therapy must pay the equivalent of US\$ 12 per dialysis session \[US\$ 1248 per annum, which is almost the gross national income per capita of US\$ 1270 in 2013\] in addition to the costs of caring for comorbidities \[[@CR29]--[@CR31]\].

Strengths and limitations {#Sec13}
-------------------------

The present study has some limitations including the semi-quantitative assessment of urinary albumin excretion using dipsticks, the non-validation of any of the equations used in SSA populations and the lack of three months control of positive findings to confirm the chronicity of renal injury as recommended by the KDIGO guidelines \[[@CR19]\]. However, previous studies from Ghana and South Africa have found a high agreement between ethnicity corrected MDRD and CKD-EPI equations, supporting their use in this setting \[[@CR13], [@CR14]\]. Moreover, by conducting this study in only one urban health district of the country, there is little opportunity of assessing variations in the prevalence of CKD across the gradient of urbanization in the country. Lastly, the study was likely underpowered to reliably investigate the determinants of the disease. However, this study to our knowledge is the first to use a multistage cluster sampling to provide community-based data on the epidemiology of kidney disease in the country with the three estimators of kidney function. The inclusion of participants from a cosmopolite urban health district likely captures the diversity of the national population with our results likely reflecting the national urban prevalence of CKD.

Conclusions {#Sec14}
===========

This study revealed that more than one in ten participants presented with CKD regardless the estimators used. This sizable prevalence of CKD, similar to those reported in developed countries, is driven essentially by the well-known clinical and socio-demographic risk factors for CKD. Actions are needed both to prevent further increase in the prevalence of CKD and to improve the detection and appropriate management of those with risk factors of the disease.
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